Sg3 Management, LLC Editas Medicine, Inc. Transaction History

Sg3 Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $267,872 - $525,660	-19,025 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$26.55 - $40.57 $1.69 Million - $2.58 Million	-63,475 Reduced 76.94%	19,025 $505,000
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $191,873 - $356,384	-4,886 Reduced 5.59%	82,500 $3.39 Million
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $1.25 Million - $2.31 Million	67,386 Added 336.93%	87,386 $2.59 Million
Q1 2020 May 12, 2020	BUY	$14.88 - $32.78 $297,600 - $655,600	20,000 New	20,000 $397,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $151M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.